Marc-André D'Aoust
Direttore Tecnico/Scientifico/R&S presso Medicago, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Takashi Nagao | M | - |
Medicago, Inc.
 Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Yoshihisa Sasou | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 11 anni |
| Seiichi Murakami | M | 67 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 11 anni |
| John Wallace | M | 67 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| To fart Luongo | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 11 anni |
| Matsuo Kikuchi | M | 64 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 8 anni |
| Christina Cameron | F | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Toshifumi Tada | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 6 anni |
| Andrew Sheldon | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Bruce Clark | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 7 anni |
| Pierre des Marais | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 4 anni |
| Carolyn Finkle | F | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 2 anni |
| Randal Chase | M | 74 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 10 anni |
| Pierre Seccareccia | M | 77 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Pierre Labbé | M | 58 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 9 anni |
| Jonathan Goodman | M | 56 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Pierre Johnson | M | 77 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Nathalie Landry | F | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Paul G. Marshall | M | 64 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Brigitte Barbeau | F | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 4 anni |
| Frédéric Ors | M | 50 |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Todd Lewis Talarico | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Yatika Kohli | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | - |
| Damien Levesque | M | - |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | 10 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Canada | 24 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Marc-André D'Aoust
- Contatti personali
